Home > CCOAT and malaria news

In the News

Launch of E8 Malaria Posts in Namaacha and Moamba, Mozambique

Listen to Dr. Phumla Sinxadi and others talk on the cost of curing disease here.

The local South African government released a press statement on World Malaria Day 2016 describing the current local and international thinking on Malaria. Read the press statement here .

UCT's H3D Partners with Janssen Pharmaceutical Companies to Advance Drug Development in Africa. Read more about the partnership here 

Since the establishment of WWARN in 2009, research partners from over 260 institutions globally have worked with WWARN, and over 120,000 individual patient records have been contributed to the WWARN Data Centre. That equates to around 80% of all the available artemisinin combination therapy trial data.Read more

Strength in standardisation: developing CDISC standards for malaria. “We are now at the forefront of developing a data standard for the malaria research community. The aim of this initiative is to support the efficient, scientifically valid, generation and reporting of malaria clinical data, and to conform to regulatory requirements for registration of new antimalarial compounds,” says Lesley Workman, Coordinator of the WWARN Pharmacology Group who is leading on the CDISC project. Read more

The malaria parasite is adept at developing drug resistance, with resistance to the artemisinin-based compounds that form the backbone of effective malaria treatment spreading rapidly across South East Asia and nearing the Indian border.” says Professor Karen Barnes.  Read a comprehensive article on Malaria in the SADC region and globally here .

Evidence to inform equitable dosing in very young and malnourished children. Our research provides health workers and researchers with an improved definition of the day 7 lumefantrine concentration threshold, which will help them to understand if treatment failure is caused by drug resistant malaria parasites or by inadequate drug concentrations, " Professor Karen Barnes (UCT). Visit http://www.wwarn.org/news for more information.

First African antimalarial to enter clinical trial. “We need to debunk the myth that Africa cannot be a source of health innovation,” says Kelly Chibale, director of the Drug Discovery and Development Centre at the University of Cape Town, South Africa. Visit http://www.scidev.net/global/health/multimedia/african-antimalarial-health-clinical-trial.html for the full article

CLINICAL DRUG TRIALS: Tests of progress. The Financial Mail reported on the launch of the UCT Clinical Research Centre's phase one unit in the article Professor Barnes, discusses the need for close monitoring during phase 1 studies  "It is a complex science to move safely and responsibly from animal and test tube studies to studies in people. We start with very low doses in small numbers of healthy people and watch them closely. If that goes well, we give slightly more, gradually building up until we get past the dose that we guess will be effective," Read the full article here